Emily Kenner, MD
Nephrology · Edgewood, KYNPI 1225201858
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Amgen at 50.0% of the total. Reporting peaked in 2021 at $2,336 and has fallen 81.8% since, to $424 in 2025.
Across 161 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AstraZeneca$596
- Vifor Pharma, Inc.$426
- Travere Therapeutics, Inc.$240
- Calliditas Therapeutics US Inc.$236
- Otsuka America Pharmaceutical, Inc.$189
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$2,35044%
- Food & beverage$3,02756%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 35 | $2,690 |
| AstraZeneca(2 entities) | 17 | $596 |
| Vifor Pharma, Inc. | 21 | $426 |
| Travere Therapeutics, Inc. | 16 | $240 |
| Calliditas Therapeutics US Inc. | 9 | $236 |
| Otsuka America Pharmaceutical, Inc. | 9 | $189 |
| OPKO Pharmaceuticals, LLC | 8 | $134 |
| Aurinia Pharma U.S., Inc. | 5 | $119 |
| Recordati_rare_diseases_inc. | 5 | $96 |
| Novo Nordisk | 4 | $74 |
| Bayer | 4 | $68 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Leadiant Biosciences, Inc. | 2 | $57 |
| ANI Pharmaceuticals, Inc. | 3 | $54 |
| GSK | 3 | $54 |
| Akebia Therapeutics Inc | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Covidien LP | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Novartis | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,386 in reported general payments places this provider in the 80th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CystadropsCysteamine Hcl | 24 | $222,024 |
| FarxigaDapagliflozin Propanediol | 81 | $84,548 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $11,929 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $10,547 |
| EliquisApixaban | 11 | $6,431 |
| Torsemide | 224 | $4,756 |
| Potassium Chloride | 131 | $4,385 |
| Potassium Citrate ErPotassium Citrate | 48 | $4,265 |
| ProsolParenteral Amino Acid 20% No.1 | 19 | $3,364 |
| Losartan Potassium | 304 | $3,057 |
| Sevelamer Carbonate | 29 | $2,758 |
| Calcitriol | 145 | $1,927 |
| Eplerenone | 20 | $1,716 |
| Nifedipine ErNifedipine | 72 | $1,628 |
| Hydralazine Hcl | 78 | $1,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Recordati_rare_diseases_inc.Cystadrops | $96 | $222,02424 claims |
| AstraZenecaFarxiga, Lokelma | $596 | $96,47792 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $54 | $1,11842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Edgewood
- Rakesh KumarEdgewood$4K
- Isaac ThomasEdgewood$3K
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Javier Neyra LozanoLexington$181K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Ravinder BhagrathPikeville$84K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.